Taysha Gene Therapies IncNASDAQ:TSHA
- LAST PRICE3.2400
- TODAY'S CHANGE (%)0.2400 (8.0000%)
- Bid / Lots3.2400/ 14
- Ask / Lots3.2700/ 2
- Open / Previous Close3.0100 / 3.0000
- Day Range
- 52 Week Range
- Volume2,242,531
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TSHA |
|---|---|---|
| 09:32 ET | 7562 | 3.02 |
| 09:33 ET | 13733 | 3.05 |
| 09:35 ET | 54851 | 3.09 |
| 09:37 ET | 10801 | 3.085 |
| 09:39 ET | 6429 | 3.07 |
| 09:42 ET | 7459 | 3.05 |
| 09:44 ET | 11243 | 3.0926 |
| 09:46 ET | 10645 | 3.12 |
| 09:48 ET | 24724 | 3.135 |
| 09:50 ET | 26215 | 3.135 |
| 09:51 ET | 25727 | 3.1 |
| 09:53 ET | 15026 | 3.095 |
| 09:55 ET | 53882 | 3.115 |
| 09:57 ET | 36848 | 3.12 |
| 10:00 ET | 9277 | 3.115 |
| 10:02 ET | 4892 | 3.14 |
| 10:04 ET | 44582 | 3.15 |
| 10:06 ET | 20255 | 3.155 |
| 10:08 ET | 11200 | 3.165 |
| 10:09 ET | 65708 | 3.1643 |
| 10:11 ET | 68321 | 3.205 |
| 10:13 ET | 9201 | 3.205 |
| 10:15 ET | 59269 | 3.16 |
| 10:18 ET | 10209 | 3.145 |
| 10:20 ET | 62414 | 3.1 |
| 10:22 ET | 12902 | 3.11 |
| 10:24 ET | 22490 | 3.115 |
| 10:26 ET | 21346 | 3.09 |
| 10:27 ET | 11044 | 3.1 |
| 10:29 ET | 2639 | 3.11 |
| 10:31 ET | 14315 | 3.115 |
| 10:33 ET | 15677 | 3.12 |
| 10:36 ET | 77594 | 3.13 |
| 10:38 ET | 23289 | 3.115 |
| 10:40 ET | 7450 | 3.105 |
| 10:42 ET | 7329 | 3.105 |
| 10:44 ET | 2276 | 3.105 |
| 10:47 ET | 3905 | 3.115 |
| 10:49 ET | 5666 | 3.12 |
| 10:51 ET | 14234 | 3.125 |
| 10:54 ET | 2809 | 3.125 |
| 10:56 ET | 16412 | 3.135 |
| 10:58 ET | 7613 | 3.165 |
| 11:00 ET | 24395 | 3.145 |
| 11:02 ET | 900 | 3.15 |
| 11:03 ET | 4360 | 3.15 |
| 11:05 ET | 600 | 3.16 |
| 11:07 ET | 400 | 3.155 |
| 11:09 ET | 24523 | 3.165 |
| 11:12 ET | 6175 | 3.175 |
| 11:14 ET | 22125 | 3.155 |
| 11:16 ET | 9757 | 3.145 |
| 11:18 ET | 6943 | 3.14 |
| 11:20 ET | 500 | 3.135 |
| 11:21 ET | 4543 | 3.14 |
| 11:23 ET | 2750 | 3.145 |
| 11:25 ET | 14642 | 3.13 |
| 11:27 ET | 1116 | 3.13 |
| 11:30 ET | 7812 | 3.115 |
| 11:32 ET | 600 | 3.125 |
| 11:34 ET | 2791 | 3.12 |
| 11:36 ET | 2308 | 3.125 |
| 11:38 ET | 3828 | 3.12 |
| 11:39 ET | 600 | 3.13 |
| 11:41 ET | 7259 | 3.14 |
| 11:43 ET | 14557 | 3.1501 |
| 11:45 ET | 3512 | 3.16 |
| 11:48 ET | 5099 | 3.16 |
| 11:50 ET | 10340 | 3.18 |
| 11:52 ET | 18000 | 3.1802 |
| 11:54 ET | 28362 | 3.185 |
| 11:56 ET | 64498 | 3.185 |
| 11:57 ET | 312 | 3.185 |
| 11:59 ET | 400 | 3.185 |
| 12:01 ET | 7670 | 3.185 |
| 12:03 ET | 8718 | 3.19 |
| 12:06 ET | 80613 | 3.23 |
| 12:08 ET | 36810 | 3.2 |
| 12:10 ET | 200 | 3.2 |
| 12:12 ET | 600 | 3.2 |
| 12:14 ET | 6170 | 3.2 |
| 12:15 ET | 2000 | 3.2 |
| 12:17 ET | 20520 | 3.19 |
| 12:19 ET | 6360 | 3.19 |
| 12:21 ET | 7578 | 3.21 |
| 12:24 ET | 10677 | 3.225 |
| 12:26 ET | 16578 | 3.21 |
| 12:28 ET | 8482 | 3.225 |
| 12:30 ET | 4474 | 3.24 |
| 12:32 ET | 2056 | 3.24 |
| 12:33 ET | 5950 | 3.25 |
| 12:35 ET | 42365 | 3.255 |
| 12:37 ET | 6700 | 3.255 |
| 12:39 ET | 7972 | 3.27 |
| 12:42 ET | 37332 | 3.275 |
| 12:44 ET | 729 | 3.275 |
| 12:46 ET | 52099 | 3.275 |
| 12:48 ET | 3000 | 3.28 |
| 12:50 ET | 6971 | 3.275 |
| 12:51 ET | 23584 | 3.27 |
| 12:53 ET | 5345 | 3.2701 |
| 12:55 ET | 63011 | 3.26 |
| 12:57 ET | 64666 | 3.24 |
| 01:00 ET | 249706 | 3.24 |
Nov 15, 2024
DJ Taysha Gene Therapies Is Maintained at Buy by Canaccord Genuity, from 9:41AM ET on Friday Nov 15, 2024 by Dow Jones
9:41AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
DJ Taysha Gene Therapies Price Target Maintained With a $6.00/Share by Needham, from 1:54PM ET on Thursday Nov 14, 2024 by Dow Jones
1:54PM ET on Thursday Nov 14, 2024 by Dow JonesDJ Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 9:11AM ET on Thursday Nov 14, 2024 by Dow Jones
9:11AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
*DJ Taysha Gene Therapies 3Q Loss/Shr 10c >TSHA, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 13, 2024 by Dow JonesTaysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Taysha Gene Therapies Inc | 600.5M | -51.8x | --- |
Arbutus Biopharma Corp | 646.2M | -8.1x | --- |
Stoke Therapeutics Inc | 623.4M | -5.8x | --- |
Mereo BioPharma Group PLC | 552.3M | 0.0x | --- |
SS Innovations International Inc | 632.2M | -22.6x | --- |
Corvus Pharmaceuticals Inc | 605.3M | -9.8x | --- |
Company Information
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.
Contact Information
- Headquarters
- 3000 Pegasus Park Drive, Suite 1430DALLAS, TX, United States 75247
- Phone
- 214-612-0000
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Sean Nolan
- President, Head of Research and Development, Director
- Sukumar Nagendran
- Chief Financial Officer
- Kamran Alam
- Director
- Alison Long
- Independent Director
- Phillip Donenberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $600.5M |
|---|---|
Revenue (TTM) | $9.9M |
Shares Outstanding | 204.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.67 |
EPS | $-0.06 |
Book Value | $0.40 |
P/E Ratio | -51.8x |
Price/Sales (TTM) | 60.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -899.35% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
